Carbetocin + Placebo
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphagia in Prader-Willi Syndrome
Conditions
Hyperphagia in Prader-Willi Syndrome
Trial Timeline
Nov 27, 2023 → Nov 1, 2025
NCT ID
NCT06173531About Carbetocin + Placebo
Carbetocin + Placebo is a phase 3 stage product being developed by Acadia Pharmaceuticals for Hyperphagia in Prader-Willi Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT06173531. Target conditions include Hyperphagia in Prader-Willi Syndrome.
What happened to similar drugs?
0 of 3 similar drugs in Hyperphagia in Prader-Willi Syndrome were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06173531 | Phase 3 | Active |
Competing Products
3 competing products in Hyperphagia in Prader-Willi Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Carbetocin | Acadia Pharmaceuticals | Phase 3 | 44 |
| Placebo + ARD-101 | Aardvark Therapeutics | Phase 3 | 34 |
| ARD-101 | Aardvark Therapeutics | Phase 3 | 34 |